Shanghai Pharmaceuticals Holding Co. Ltd. has reported interleukin-17A (IL-17A) inhibitors that are potentially useful for the treatment of psoriasis, rheumatoid arthritis, spondyloarthritis, hidradenitis suppurativa, psoriatic arthritis and uveitis.